- Zymeworks Inc (NASDAQ:ZYME) announced topline results from the pivotal Phase 2b HERIZON-BTC-01 trial investigating zanidatamab as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC).
- In October, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced to acquire rights to zanidatamab across all indications in the U.S., Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene Ltd (NASDAQ: BGNE).
- Related: Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline.
- The topline results showed that 41.3% of enrolled patients with HER2-amplified and expressing (IHC2+ and 3+) disease achieved an objective response.
- The median duration of response was 12.9 months.
- The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.
- Price Action: ZYME shares are up 4.80% at $6.77 on the last check Monday.
Welbilt Q4 EPS $0.18 Up From $0.15 YoY, Sales $423.00M Up From $320.00M YoY
Welbilt (NYSE:WBT) reported quarterly earnings of $0.18 per share. This is a 20 percent increase over earnings of $0.15 per share from the same period last year. The company reported $423.00 million in sales this
